Gram-Positive Bacterial Infections
Recent clinical, regulatory, research and industry developments relating to this disease.
Agents Targeting the Bacterial Cell Wall as Tools to Combat Gram-Positive Pathogens.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q2 2029.
Clinical MilestonesViewHide
- 2026-04-14ClinicalA Follow-up Trial to Assess the Persistence of the Immune Response to the Group B Streptococcus Vaccine (GBS-NN/NN2) After a Primary Vaccination of Healthy Pregnant Women, and to Assess Safety, Reactogenicity, and Immunogenicity of the GBS-NN/NN2 Vaccine When Administered During Follow-Up as a 1 Booster Dose During a New PregnancyResults expected Q2 2029
- 2025-11-04ClinicalAn Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of Oritavancin Single Dose Infusion in Pediatric Subjects Less Than 18 Years of Age With Suspected or Confirmed Bacterial InfectionsCompleted
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes5
- Anti-Bacterial Agents1
- Cell Wall1
- Drosophila Proteins1
- Genome, Bacterial1
- Gram-Positive Bacteria1
Leading journals6
- BMC genomics1
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America1
- F1000Research1
- Immunological reviews1
- Journal of immunology (Baltimore, Md. : 1950)1
- Molecules (Basel, Switzerland)1
Leading researchers8
- Bischoff T1
- Bohne W1
- Bonar E1
- Brzuszkiewicz E1
- Bukowski M1
- Bunk B1
- Chibani C1
- Daniel R1
Affiliations (unnormalised)6
- Andreas Syggros Hospital1
- Department of Genomic and Applied Microbiology & Göttingen Genomics Laboratory1
- Doctoral School of Exact and Natural Sciences1
- German Center for Infection Research (DZIF)1
- Institute for Medical Microbiology1
- Jagiellonian University1
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Gram-positive bacterial infections are infections caused by bacteria that retain the crystal violet stain on Gram staining. They include infections due to a broad group of Gram-positive pathogens, and the literature emphasizes their clinical importance as targets of antibacterial therapy.
They are caused by infection with Gram-positive bacteria. The supplied grounding does not support a more specific aetiology beyond bacterial infection.
The grounding supports bacterial cell wall biology as a key mechanism relevant to Gram-positive pathogens, since the cell wall is an indispensable bacterial structure and a major antibiotic target. Microbial drug resistance is also highlighted as an important mechanism shaping persistence and treatment failure in these infections.
Treatment is generally centered on antibacterial therapy, especially agents targeting the bacterial cell wall such as beta-lactam antibiotics. The literature also emphasizes the growing importance of managing multidrug-resistant Gram-positive pathogens, which has driven interest in novel cell-wall-targeting approaches.
AI-generated summary grounded in MeSH and 3 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.